Department of Neurosurgery, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, PHC 7, Washington, DC, USA.
School of Medicine, Georgetown University, Washington, DC, USA.
Neurocrit Care. 2022 Jun;36(3):916-926. doi: 10.1007/s12028-021-01399-7. Epub 2021 Nov 30.
Patients with aneurysmal subarachnoid hemorrhage (aSAH) may develop refractory arterial cerebral vasospasm requiring multiple endovascular interventions. The aim of our study is to evaluate variables associated with need for repeat endovascular treatments in refractory vasospasm and to identify differences in outcomes following one versus multiple treatments.
We retrospectively reviewed patients treated for aSAH between 2017 and 2020 at two tertiary care centers. We included patients who underwent treatment (intraarterial infusion of vasodilatory agents or mechanical angioplasty) for radiographically diagnosed vasospasm in our analysis. Patients were divided into those who underwent single treatment versus those who underwent multiple endovascular treatments for vasospasm.
Of the total 418 patients with aSAH, 151 (45.9%) underwent endovascular intervention for vasospasm. Of 151 patients, 95 (62.9%) underwent a single treatment and 56 (37.1%) underwent two or more treatments. Patients were more likely to undergo multiple endovascular treatments if they had a Hunt-Hess score > 2 (odds ratio [OR] 5.10 [95% confidence interval (CI) 1.82-15.84]; p = 0.003), a neutrophil-to-lymphocyte ratio > 8.0 (OR 3.19 [95% CI 1.40-7.62]; p = 0.028), and more than two fevers within the first 5 days of admission (OR 7.03 [95% CI 2.68-20.94]; p < 0.001). Patients with multiple treatments had poorer outcomes, including increased length of stay, delayed cerebral ischemia, in-hospital complications, and higher modified Rankin scores at discharge.
A Hunt-Hess score > 2, a neutrophil-to-lymphocyte ratio > 8.0, and early fevers may be predictive of need for multiple endovascular interventions in refractory cerebral vasospasm after aSAH. These patients have poorer functional outcomes at discharge and higher rates of in-hospital complications.
患有动脉瘤性蛛网膜下腔出血(aSAH)的患者可能会出现难治性动脉性脑血管痉挛,需要多次血管内介入治疗。我们的研究目的是评估与难治性血管痉挛需要重复血管内治疗相关的变量,并确定单次与多次治疗后的结果差异。
我们回顾性分析了 2017 年至 2020 年在两家三级保健中心接受治疗的 aSAH 患者。我们将接受血管造影诊断为血管痉挛的患者纳入分析。将患者分为单次治疗组和多次血管内治疗组。
在总计 418 例 aSAH 患者中,151 例(45.9%)因血管痉挛行血管内介入治疗。在 151 例患者中,95 例(62.9%)行单次治疗,56 例(37.1%)行 2 次或以上治疗。如果患者的 Hunt-Hess 评分>2(优势比[OR]5.10[95%置信区间[CI]1.82-15.84];p=0.003)、中性粒细胞与淋巴细胞比值>8.0(OR 3.19[95%CI1.40-7.62];p=0.028)或入院前 5 天内出现两次以上发热(OR 7.03[95%CI2.68-20.94];p<0.001),则更有可能行多次血管内治疗。行多次治疗的患者预后较差,包括住院时间延长、迟发性脑缺血、院内并发症和出院时改良 Rankin 评分较高。
Hunt-Hess 评分>2、中性粒细胞与淋巴细胞比值>8.0 和早期发热可能预示着 aSAH 后难治性脑血管痉挛需要多次血管内介入治疗。这些患者出院时的功能预后较差,院内并发症发生率较高。